These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A; De Leo V Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832 [TBL] [Abstract][Full Text] [Related]
4. Advances in oral contraception. An international review of levonorgestrel and ethinyl estradiol. Goldzieher JW J Reprod Med; 1983 Jan; 28(1 Suppl):53-6. PubMed ID: 6403700 [TBL] [Abstract][Full Text] [Related]
5. The triphasics: insights for effective clinical use. Youngkin EQ; Miller LG Nurse Pract; 1987 Feb; 12(2):17-8, 23, 26-8. PubMed ID: 3822267 [TBL] [Abstract][Full Text] [Related]
6. Oral contraceptives and the risk of cardiovascular disease. Med Lett Drugs Ther; 1983 Jul; 25(640):69-70. PubMed ID: 6865850 [TBL] [Abstract][Full Text] [Related]
7. The use of newer progestins for contraception. Sitruk-Ware R; Nath A Contraception; 2010 Nov; 82(5):410-7. PubMed ID: 20933114 [TBL] [Abstract][Full Text] [Related]
8. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene]. Belaisch J; Hommais-loufrani B Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078 [TBL] [Abstract][Full Text] [Related]
10. [Oral contraception: disadvantages of estrogen reduction]. Denis C Contracept Fertil Sex (Paris); 1993 Jun; 21(6):481-8. PubMed ID: 12318238 [TBL] [Abstract][Full Text] [Related]
11. [Do's and don'ts for a woman who has an abnormal lipid pattern and is taking oral contraceptives]. Boyet F Contracept Fertil Sex (Paris); 1984 Sep; 12(9):1076-7. PubMed ID: 12266510 [TBL] [Abstract][Full Text] [Related]
12. Biological activity of oral contraceptives. Stubblefield PG Int J Fertil; 1986; 31 SU [UPDATE]():4-12. PubMed ID: 2899558 [TBL] [Abstract][Full Text] [Related]
13. [Clinical study of a low-dose contraceptive--Femodene]. Rachev E; Damianov L; Dukovski A; Katsarova M Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249 [TBL] [Abstract][Full Text] [Related]
15. [Influence of progestins on adverse effects of oral contraceptives]. Wynn V Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210 [TBL] [Abstract][Full Text] [Related]
16. Present status of oral contraceptives: 1. effectiveness; basis for selection; side effects; metabolic changes. Kistner RW Drug Ther (NY); 1971 Dec; 1(12):14-29. PubMed ID: 12306285 [TBL] [Abstract][Full Text] [Related]
17. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data]. Gaspard U; Dubois M Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606 [TBL] [Abstract][Full Text] [Related]
18. Clinical experience with a low-dose contraceptive agent. European studies. Haspels AA J Reprod Med; 1983 Jan; 28(1 Suppl):71-6. PubMed ID: 6403703 [TBL] [Abstract][Full Text] [Related]
19. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or 30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density. Endrikat J; Mih E; Düsterberg B; Land K; Gerlinger C; Schmidt W; Felsenberg D Contraception; 2004 Mar; 69(3):179-87. PubMed ID: 14969664 [TBL] [Abstract][Full Text] [Related]